- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04248439
Gene Therapy for Fanconi Anemia, Complementation Group A
A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects With Fanconi Anemia Subtype A
The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A).
Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will be infused intravenously back to the patient with the goal of preventing bone marrow failure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pediatric open-label Phase II clinical trial to assess the efficacy of a hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with FA-A.
Enriched CD34+ hematopoietic stem cells will be transduced ex vivo with the therapeutic lentiviral vector and infused via intravenous infusion following transduction without any prior conditioning.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Clinical Information
- Phone Number: 646-627-0033
- Email: FAclinicaltrial@rocketpharma.com
Study Locations
-
-
California
-
Stanford, California, United States, 94304
- Stanford University
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55454
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Fanconi anemia as diagnosed by chromosomal fragility assay of cultured lymphocytes in the presence of DEB or a similar DNA-crosslinking agent
- Subject of the complementation group FA-A
- Minimum age: 1 year and a minimum weight of 8 kg
- At least 30 CD34+ cells/μL are determined in one bone marrow (BM) aspiration within 3 months prior to CD34+ cell collection OR
6. Provide informed consent in accordance with current legislation 7. Women of childbearing age must have a negative urine pregnancy test at the baseline visit, and accept the use of an effective contraception method during participation in the trial
Exclusion Criteria:
- Subjects with an available and medically eligible HLA-identical sibling donor.
- Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities other than those reported as variant(s) of normal in BM aspirate analysis. This assessment should be made by valid studies conducted within the 3 months before the subject commences the stem cell mobilization/collection procedures of the clinical trial.
- Subjects with somatic mosaicism associated with stable or improved counts in all PB cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential mosaicism, a medically significant decrease (≥1 NCI CTCAE grade) in at least one blood lineage over time must be documented to enable eligibility, as should <5% resistance of bone marrow colony forming cells (CFCs) to 10nM MMC; whenever possible potential mosaicism should also be evaluated by gene sequencing of MMC-resistant CFCs).
- Lansky performance status ≤60%.
- Any concomitant disease or condition that, in the opinion of the Principal Investigator, renders the subject unfit to participate in the study.
- Pre-existing sensory or motor impairment ≥grade 2 according to the criteria of the NCI.
- Pregnant or breastfeeding women.
Hepatic dysfunction as defined by either:
- Bilirubin >3.0 × the upper limit of normal (ULN) or
- Alanine aminotransferase (ALT) > 5.0 × ULN or
- Aspartate aminotransferase (AST) > 5.0 × ULN
For subjects with bilirubin, ALT or AST above ULN, a workup to identify the etiology of liver abnormality should be conducted prior to confirmation of eligibility as stipulated in exclusion criterion 5, including evaluation of viral hepatitis, iron overload, drug injury or other causes.
- Renal dysfunction requiring either hemodialysis or peritoneal dialysis.
Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks in absence of acute infection or
- Oxygen saturation by pulse oximetry <90%.
- Evidence of active metastatic or locoregionally advanced malignancy for which survival is anticipated to be less than 3 years.
- Subject is receiving androgens (i.e. danazol, oxymetholone).
- Subject is receiving other investigational therapy for treatment/prevention of FA-associated bone marrow failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RP-L102
RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
|
CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone Marrow (BM) Colony-Forming Cell (CFC) Mitomycin-C (MMC) resistance
Time Frame: 21 months
|
Bone Marrow (BM) colony-forming cell (CFC) mitomycin-C (MMC) resistance ≥20% at 12 months post-infusion with a confirmatory result at 18 or 21 months (MMC at 10 nM concentration)
|
21 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Genetic Correction
Time Frame: 24 months
|
Evidence of genetic correction as demonstrated by ≥0.1 VCN level of FANCA-LV provirus in total PB cells at 18 months post-infusion with a confirmatory result at 21 or 24 months
|
24 months
|
Hematologic Stability- Hemoglobin
Time Frame: 24 months
|
Hematologic stability demonstrated by hemoglobin levels remaining ≥75% of 6-month post-infusion nadir value, in the absence of Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and/or progressive cytogenetic and/or molecular abnormalities known to be associated with MDS/AML at 18 months post-infusion with a confirmatory result at 21 or 24 months. In settings in which 6-month post-infusion neutrophil or platelet values are demonstrably increased relative to other values during the initial year post-infusion, especially in situations of documented infections or febrile episodes, the value from the most proximate prior visit at which there is no documented infection or febrile episode is used. Levels must exceed the following values at the latest documented assessment (≥18 months post-infusion): hemoglobin ≥8 g/dL (National Cancer Institute-Common Terminology Criteria Adverse Events (NCI-CTCAE) v5 Grade <3). |
24 months
|
Hematologic Stability- Neutrophils
Time Frame: 24 months
|
Hematologic stability demonstrated by neutrophil count remaining ≥75% of 6-month post-infusion nadir value, in the absence of Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and/or progressive cytogenetic and/or molecular abnormalities known to be associated with MDS/AML at 18 months post-infusion with a confirmatory result at 21 or 24 months. In settings in which 6-month post-infusion neutrophil or platelet values are demonstrably increased relative to other values during the initial year post-infusion, especially in situations of documented infections or febrile episodes, the value from the most proximate prior visit at which there is no documented infection or febrile episode is used. Levels must exceed the following values at the latest documented assessment (≥18 months post-infusion): neutrophils ≥500/µL (NCI-CTCAE v5 Grade <4). |
24 months
|
Hematologic Stability- Platelets
Time Frame: 24 months
|
Hematologic stability demonstrated by Platelet count remaining ≥75% of 6-month post-infusion nadir value, in the absence of Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and/or progressive cytogenetic and/or molecular abnormalities known to be associated with MDS/AML at 18 months post-infusion with a confirmatory result at 21 or 24 months. In settings in which 6-month post-infusion neutrophil or platelet values are demonstrably increased relative to other values during the initial year post-infusion, especially in situations of documented infections or febrile episodes, the value from the most proximate prior visit at which there is no documented infection or febrile episode is used. Levels must exceed the following values at the latest documented assessment (≥18 months post-infusion): platelets ≥25,000/µL (NCI-CTCAE v5 Grade <4). |
24 months
|
Phenotypic Correction
Time Frame: 24 months
|
In patients who were not mosaic in Peripheral Blood T-cells prior to gene therapy, the level of phenotypic correction of hematopoietic cells as determined by a T-lymphocyte chromosomal fragility assay targeting a decrease from ≥50% pre-infusion levels to <50% in Peripheral Blood T-cells with DEB-induced aberrations and a ≥20% decrease from pre-treatment levels at ≥182 months post-infusion with a confirmatory result at 21 or 24 months
|
24 months
|
Safety of RP-L102
Time Frame: 3 years
|
Analysis of Treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs), for the duration of the study.
|
3 years
|
Tolerability of RP-L102
Time Frame: 3 years
|
Analysis of Treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs), for the duration of the study.
|
3 years
|
Overall survival
Time Frame: 3 years
|
Survival at end of study
|
3 years
|
Bone Marrow Failure Free Survival
Time Frame: 3 years
|
Bone Marrow Failure Free at end of study
|
3 years
|
Hematological Malignancy Free Survival
Time Frame: 3 years
|
Lack of Myelodysplastic Syndrome or Acute Myeloid Leukemia at end of study
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Margaret MacMillan, MD, MSc, University of Minnesota
- Principal Investigator: Rajni Agarwal, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Bone Marrow Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- DNA Repair-Deficiency Disorders
- Anemia, Hypoplastic, Congenital
- Anemia, Aplastic
- Congenital Bone Marrow Failure Syndromes
- Bone Marrow Failure Disorders
- Renal Tubular Transport, Inborn Errors
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Anemia
- Fanconi Syndrome
- Fanconi Anemia
Other Study ID Numbers
- RP-L102-0319
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fanconi Anemia Complementation Group A
-
Rocket Pharmaceuticals Inc.Active, not recruitingFanconi Anemia Complementation Group ASpain
-
Rocket Pharmaceuticals Inc.UnknownFanconi Anemia Complementation Group AUnited States
-
Rocket Pharmaceuticals Inc.Enrolling by invitationFanconi Anemia | Fanconi Anemia Complementation Group ASpain
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingBile Duct Adenocarcinoma | Fanconi Anemia Complementation Group Gene Mutation | Metastatic Bile Duct Carcinoma | PTEN Gene DeletionUnited States
-
Noordwest ZiekenhuisgroepKarolinska Institutet; Medical University of Graz; Fondazione Policlinico Universitario... and other collaboratorsRecruitingInvasive Group A Beta-Haemolytic Streptococcal DiseaseNetherlands
-
Tampere University HospitalTurku University Hospital; University of TurkuActive, not recruitingInvasive Group A Beta-Haemolytic Streptococcal DiseaseFinland
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of Medicine; University of...TerminatedFANCONI ANEMIAUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Rambam Health Care CampusUnknownGroup A- 23 Implant Using Switch Platform -SPK Abutment. | Group B- 22 Implant Using the Traditional -CPK Abutment.Israel
Clinical Trials on RP-L102
-
Rocket Pharmaceuticals Inc.UnknownFanconi Anemia Complementation Group AUnited States
-
Rocket Pharmaceuticals Inc.Active, not recruitingFanconi Anemia Complementation Group ASpain
-
Ewha Womans UniversityCompletedOsteoarthritisKorea, Republic of
-
European Organisation for Research and Treatment...RecruitingAll Tumor TypesSpain, United Kingdom, Croatia, Belgium, France, Netherlands, Italy, Germany, Portugal, Austria, Cyprus, Czechia, Estonia, Greece, Lithuania, Poland, Romania, Slovenia, Switzerland, Serbia
-
DePuy InternationalTerminated
-
Repare TherapeuticsDebiopharm International SARecruitingAdvanced Solid TumorUnited States, Canada, Denmark
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedObsessive-Compulsive DisorderUnited States
-
Swiss Group for Clinical Cancer ResearchTerminated
-
Rocket Pharmaceuticals Inc.RecruitingPKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)United States
-
Rocket Pharmaceuticals Inc.California Institute for Regenerative Medicine (CIRM)CompletedLeukocyte Adhesion Defect - Type ISpain, United States, United Kingdom